Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

Edward Keystone; Robert Landewé; Ronald van Vollenhoven; Bernard Combe; Vibeke Strand; Philip Mease; Laura Shaughnessy; Brenda VanLunen; Désirée van der Heijde

首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

【24h】

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

机译：塞妥珠单抗聚乙二醇乙二醇酯与甲氨蝶呤联合治疗类风湿性关节炎的长期安全性和有效性：RAPID 1试验和开放标签扩展的5年结果。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

CZP+MTX treatment provided a favourable risk-benefit profile over 5 years in patients with active RA. No new safety signals were identified.

机译：对于活动性RA患者，CZP + MTX治疗在5年内提供了有利的风险收益特征。没有发现新的安全信号。

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2014年第12期|共7页
作者
Edward Keystone; Robert Landewé; Ronald van Vollenhoven; Bernard Combe; Vibeke Strand; Philip Mease; Laura Shaughnessy; Brenda VanLunen; Désirée van der Heijde;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. [J] . Edward Keystone, Robert Landewé, Ronald van Vollenhoven, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2014,第12期

机译：塞妥珠单抗聚乙二醇乙二醇酯与甲氨蝶呤联合治疗类风湿性关节炎的长期安全性和有效性：RAPID 1试验和开放标签扩展的5年结果。
2. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study [J] . TanakaY., YamamotoK., TakeuchiT., Modern rheumatology . 2014,第5期

机译：赛妥珠单抗聚乙二醇醚对甲氨蝶呤反应不良的日本类风湿性关节炎患者的长期疗效和安全性：J-RAPID研究的开放标签扩展结果为52周
3. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients [J] . Josef S. Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, Arthritis Research . 2015,第1期

机译：类风湿关节炎预防结构性损伤（RAPID）2随机对照试验和长期延长类风湿关节炎患者的西妥昔单抗-吡咯醇加甲氨蝶呤的5年结果
4. Optimizing long-term treatment of rheumatoid arthritis with systematic documentation [C] . Simonic K. M., Holzinger A., Bloice M., 2011 5th International Conference on Pervasive Computing Technologies for Healthcare and Workshops . 2011

机译：系统化文献优化风湿性关节炎的长期治疗
5. Development and characterization of methotrexate loaded poly(L-lactic acid) microspheres for the treatment of rheumatoid arthritis. [D] . Liang, Sanching Linda. 2006

机译：甲氨蝶呤负载聚（L-乳酸）微球的开发和表征，用于治疗类风湿关节炎。
6. Extended report: Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension [O] . Edward Keystone, Robert Landewé, Ronald van Vollenhoven, -1

机译：扩展报告：certolizumab聚乙二醇单药与甲氨蝶呤联合治疗类风湿性关节炎的长期安全性和有效性：RAPID 1试验和开放标签扩展的5年结果
7. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension [O] . Keystone, Edward, Landewé, Robert, van Vollenhoven, Ronald, 2014

机译：塞妥珠单抗聚乙二醇乙二醇酯与甲氨蝶呤联合治疗类风湿性关节炎的长期安全性和有效性：RAPID 1试验和开放标签扩展的5年结果

Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.

摘要

著录项

相似文献

相关主题

期刊订阅